| Literature DB >> 12135541 |
Brian Paul Blum1, J John Mann.
Abstract
A defect in neurotransmission involving gamma-amino butyric acid (GABA) in schizophrenia was first proposed in the early 1970s. Since that time, a considerable effort has been made to find such a defect in components of the GABAergic system. After a brief introduction focusing on historical perspectives, this paper reviews post-mortem and other biological studies examining the following components of the GABAergic system in schizophrenic subjects: the GABA biosynthetic enzyme, glutamate decarboxylase; free GABA; the GABA transporter; the GABAA, GABAB and benzodiazepine receptors; and the catabolic enzyme GABA transaminase. Additionally, post-mortem studies using morphology or calcium-binding protein to identify GABAergic neurons are also reviewed. Substantial evidence argues for a defect in the GABAergic system of the frontal cortex in schizophrenia which is limited to the parvalbumin-class of GABAergic interneurons.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12135541 DOI: 10.1017/S1461145702002894
Source DB: PubMed Journal: Int J Neuropsychopharmacol ISSN: 1461-1457 Impact factor: 5.176